Advice for Clinicians on JAK Inhibitors
Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.
Treating Atopic Dermatitis with Ruxolitinib
Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.
Risk of Systemic Absorption with JAK Inhibitors
Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.
Reviewing Clinical Trial Data for JAK Inhibitors
Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.
Safety and Efficacy of JAK Inhibitors
Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.
An Overview of JAK Inhibitors
Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.
2 Clarke Drive Cranbury, NJ 08512